Project Grant R21DE032806
- This $453,750 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to investigate the genetic and cellular mechanisms underlying craniosynostosis, a common craniofacial birth defect. The research team at Boston University Medical Campus will use a zebrafish model to study the role of the ERF transcription factor in normal skull development and how its reduction...
- This $451,000 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 - Child Health and Human Development Extramural Research will support research to elucidate the role of the KBTBD2 gene in bone development and its relation to the genetic disorder Short Syndrome. The key objectives are to: 1) Determine the molecular mechanism by which KBTBD2 regulates bone development through its interaction with the p85a subunit of PI3K, a key...
- This $461,375 Project Grant, awarded by the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121), funds research conducted by Yale University from July 1, 2025, through June 30, 2027. The research addresses the molecular mechanisms underlying Coffin-Lowry Syndrome, an X-linked dominant condition caused by loss-of-function mutations in Ribosomal Protein S6 Kinase 2 (RSK2). The project will deliver comprehensive...
- This $596,378 Project Grant, awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the etiology and treatment of skeletal defects caused by spermine synthase deficiency. The award, effective July 7, 2026, through June 30, 2031, is being executed by the University of California, Davis at its Sacramento campus. The research aims to elucidate the...
- Grant Award Summary The University of Kentucky Research Foundation received a $154,000 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective March 1, 2026 through February 28, 2027. This award funds research to elucidate the etiology of Schneckenbecken Dysplasia (SBD), a rare congenital skeletal dysplasia caused by mutations in the SLC35D1 nucleotide-sugar transporter gene. The...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $445,500 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2026 through May 31, 2028. The award funds translational biomedical research aimed at defining how dominant-negative RBPJ disease alleles impact Notch pathway outcomes and contribute to Adams-Oliver Syndrome...
- This federal Project Grant award of $160,000.00 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research by Baylor College of Medicine to elucidate the morphogenetic and molecular mechanisms by which the genes RERE and SPEN contribute to the development of congenital heart defects associated with 1p36 deletion syndrome. The research aims to determine how SPEN deficiency...
- The Research Institute At Nationwide Children's Hospital received a $644,771 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2026 through February 28, 2031. The project focuses on identifying novel genes controlling craniofacial structural development by conducting forward genetic screening in mice using N-ethyl-N-nitrosourea (ENU) mutagenesis. The...
- Federal Project Grant Award Summary Boston Children's Hospital received a $178,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 15, 2025, with completion scheduled for June 14, 2026. The grant supports the development of a bone marrow organoid system to study RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1-FPD/MM), a rare genetic disorder characterized by germline heterozygous loss-of-function...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to elucidate the role of TGF-beta signaling in craniofacial fibrous dysplasia (CFD), a debilitating skeletal disease. With total funding of $306,600 awarded on September 24, 2024, the project will investigate the mechanisms driving TGF-beta signaling in response to constitutive activation of G-protein coupled receptor...
DELINEATING MOLECULAR MECHANISM OF DEVELOPMENTAL DEFECTS OF TAR SYNDROME - PROJECT SUMMARY BIRTH DEFECTS INVOLVING SKELETAL AND CRANIOFACIAL DEVELOPMENT ARE AMONG THE MOST COMMON HUMAN CONGENITAL DISEASES WITH UNMET MEDICAL NEEDS. RECENT GENETICS STUDIES HAVE IDENTIFIED MULTIPLE ROBUST AND REPLICABLE RISK LOCI TO BE ASSOCIATED WITH THESE DEVASTATING ANOMALIES, OFFERING NEW HOPE FOR THOSE AFFLICTED. AMONG THEM IS THE DISCOVERY THAT MUTATIONS IN RBM8A CAUSE A RARE DISEASE CALLED THROMBOCYTOPENIA-ABSENT- RADIUS (TAR) SYNDROME. RBM8A GENE ENCODES A RNA-BINDING PROTEIN, YET THE PRECISE MECHANISM BY WHICH RBM8A DEFICIENCY CAUSES TISSUE-SPECIFIC ABNORMALITIES REMAINS COVERED IN MYSTERY. IN PARTICULAR, THE ROLE OF RBM8A DEFICIENCY IN SKELETAL DYSMORPHOGENESIS AND ITS DIRECT TARGETS IN BONE DEVELOPMENT ARE STILL UNKNOWN. THUS, THERE IS A CRITICAL NEED TO ELUCIDATE THE UNDERLYING MECHANISM OF RBM8A CAUSING TAR SYNDROME, THEREBY ENABLING DEVELOPMENT OF EFFECTIVE TREATMENTS. OUR ULTIMATE MISSION IS TO DEVELOP INNOVATIVE STRATEGIES FOR PREVENTION AND TREATMENT OF STRUCTURAL ABNORMALITY DISORDERS SUCH AS TAR SYNDROME. AS AN IMPORTANT STEP TOWARDS OUR GOAL, WE HAVE DEVELOPED RBM8A CONDITIONAL KNOCKOUT (CKO) MICE AND HAVE REVEALED FASCINATING DEVELOPMENTAL DEFECTS. THE OBJECTIVES OF OUR RESEARCH ARE TWOFOLD: FIRST, TO EXAMINE THE ROLE OF RBM8A IN FORELIMB DEVELOPMENT, AND SECOND, TO HARNESS THE POWER OF VIRAL GENE THERAPY TO REVERSE RADIAL DEVELOPMENT DEFECTS IN A TAR MOUSE MODEL. OUR RATIONALE FOR THIS PROJECT IS THAT ITS SUCCESSFUL COMPLETION WOULD PROVIDE A STRONG, CONCEPTUAL, EVIDENCE-BASED FRAMEWORK TO DEVELOP THERAPEUTIC STRATEGIES FOR CONGENITAL SKELETAL DISEASES. TO ACHIEVE OUR OBJECTIVES, WE WILL RIGOROUSLY TEST TWO SPECIFIC AIMS: 1) DETERMINE THE ROLE OF RBM8A IN RADIAL DEVELOPMENT; AND 2) DETERMINE THE EFFECTS OF RBM8A REINSTATEMENT THERAPY ON ANATOMICAL AND FUNCTIONAL OUTCOMES IN CKO MICE. AT THE COMPLETION OF THIS PROJECT, WE EXPECT TO DISCOVER IMPORTANT INSIGHTS ON THE MOLECULAR BASIS OF THE RADIAL DEVELOPMENT OF A CAUSAL GENE OF TAR SYNDROME. THE SUCCESSFUL COMPLETION OF THE PROPOSED STUDIES WOULD HAVE AN IMPORTANT POSITIVE IMPACT ON FUTURE DRUG SCREENING AND FURTHER DEVELOPMENT OF NOVEL THERAPEUTIC INTERVENTIONS FOR OTHER DEVELOPMENTAL DISORDERS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($252) | 2/19/26 | ||
| Not listed | $411.9k | 9/13/23 |